TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31983371

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min) combined with speech-language therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS combined with speech-language therapy
Number of subjects: 10
Study: 30373688

Group type: EXPERIMENTAL
Intervention: Single-item sleep quality scale (SQS)
Number of subjects: 721
Study: 27524671

Group type: EXPERIMENTAL
Intervention: Training group with monthly bisphosphonate regimen
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Training group with weekly bisphosphonate regimen
Number of subjects: 979

Group type: COMPARATOR
Intervention: Control group with monthly bisphosphonate regimen
Number of subjects: 979

Group type: COMPARATOR
Intervention: Control group with weekly bisphosphonate regimen
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Monthly regimen
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Weekly regimen
Number of subjects: 979
Study: 24888479

Group type: EXPERIMENTAL
Intervention: WELLFOCUS PPT (11-session group therapy in addition to treatment as usual)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 80
Study: 22876730

Group type: EXPERIMENTAL
Intervention: Upper extremity supports
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lateral trunk supports
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Anterior pelvic belt
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30 degree posterior seat tilt
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Various wheelchair configurations (conditions 1-6)
Number of subjects: 8
Study: 20816546

Group type: EXPERIMENTAL
Intervention: Oxygen delivered via nasal cannula at 2 L per min for 7 days
Number of subjects: 239

Group type: COMPARATOR
Intervention: Room air delivered via nasal cannula at 2 L per min for 7 days
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 239

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 239
Study: 18768106

Group type: EXPERIMENTAL
Intervention: Ropinirole 24-hour prolonged release
Number of subjects: 161

Group type: COMPARATOR
Intervention: Ropinirole immediate release
Number of subjects: 161
Study: 15922813

Group type: EXPERIMENTAL
Intervention: Stable dosing of salmeterol/fluticasone propionate (SAL/FP) 50/250 microg BID
Number of subjects: 688

Group type: COMPARATOR
Intervention: Adjustable maintenance dosing of formoterol/budesonide (FOR/BUD) 6/200 microg BID
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Stable dosing of SAL/FP
Number of subjects: 688

Group type: COMPARATOR
Intervention: Adjustable maintenance dosing of FOR/BUD
Number of subjects: 688
Study: 12890374

Group type: EXPERIMENTAL
Intervention: Heliox-driven beta(2)-agonist therapy (Berotec)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Compressed air-driven beta(2)-agonist therapy (Berotec)
Number of subjects: 32
Study: 10545430

Group type: EXPERIMENTAL
Intervention: 10 microg bFGF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 microg bFGF
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8886564

Group type: EXPERIMENTAL
Intervention: HOMA model assessment of insulin resistance (IR) and insulin secretion from fasting glucose and insulin concentrations.
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: HOMA model assessment of insulin secretion.
Number of subjects: 1449
Study: 1886349

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (2 x 200 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 35
Study: 6682324

Group type: EXPERIMENTAL
Intervention: Carteolol 15 mg/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pindolol 15 mg/day
Number of subjects: 49
Study: 31060979

Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Guadecitabine 90 mg/m2
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2 and 90 mg/m2
Number of subjects: 105
Study: 29924696

Group type: EXPERIMENTAL
Intervention: Compression garments (COMP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CON) - active recovery only
Number of subjects: 32
Study: 26832427

Group type: EXPERIMENTAL
Intervention: Home visit (HV)
Number of subjects: 7039

Group type: EXPERIMENTAL
Intervention: Home visit + drop-in (HV+drop-in)
Number of subjects: 7039

Group type: COMPARATOR
Intervention: Usual care (comparison arm)
Number of subjects: 7039
Study: 24387094

Group type: EXPERIMENTAL
Intervention: Group decision-making intervention (participants made decisions about lounge refurbishment as a group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison condition (staff made decisions about lounge refurbishment)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition (no treatment)
Number of subjects: 36
Study: 22000905

Group type: EXPERIMENTAL
Intervention: 25% oral glucose solution (2 mL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral sterile water (2 mL)
Number of subjects: 120
Study: 19562632

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17437473

Group type: EXPERIMENTAL
Intervention: Abbreviated schedules of preexposure tissue culture rabies vaccines
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.1 mL intradermally at two sites on one day
Number of subjects: 96
Study: 15136288

Group type: EXPERIMENTAL
Intervention: Senior Lay Health Mentoring
Number of subjects: 289
Study: 12463653

Group type: EXPERIMENTAL
Intervention: Early mobilisation at one week after operation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Late mobilisation at four weeks after operation
Number of subjects: 39
Study: 9729561

Group type: EXPERIMENTAL
Intervention: Caf capsule (4.45 mg/kg body wt)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Decaffeinated Cof
Number of subjects: 9

Group type: COMPARATOR
Intervention: Decaffeinated Cof with Caf added
Number of subjects: 9

Group type: COMPARATOR
Intervention: Regular Cof
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7640591

Group type: EXPERIMENTAL
Intervention: Primary care patients
Number of subjects: 2356

Group type: COMPARATOR
Intervention: Accident and emergency patients
Number of subjects: 2356
Study: 2534084

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dietary restriction of refined carbohydrate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (12 comparable controls)
Number of subjects: 24
Study: 4846329

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (Dexedrine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stimulant drugs (Dexedrine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Depressant drugs (Phenobarbitone)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Centrally stimulant and depressant drugs
Number of subjects: 45
Study: 31829664

Group type: EXPERIMENTAL
Intervention: Live counseling
Number of subjects: 251

Group type: COMPARATOR
Intervention: Automated content
Number of subjects: 251
Study: 30689494

Group type: EXPERIMENTAL
Intervention: CHICOS (tailored intervention)
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: Untailored intervention (iPad-based Vaccine Information Sheet)
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1294
Study: 29072001

Group type: EXPERIMENTAL
Intervention: Eye-acupuncture therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60
Study: 26165955

Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 109

Group type: COMPARATOR
Intervention: No Continuous Passive Motion (no CPM)
Number of subjects: 109
Study: 23186338

Group type: EXPERIMENTAL
Intervention: ASD patients
Number of subjects: 20
Study: 22000080

Group type: EXPERIMENTAL
Intervention: Overlapping condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-overlapping condition
Number of subjects: 0
Study: 18438851

Group type: EXPERIMENTAL
Intervention: Step-up therapy (sulfasalazine monotherapy, then methotrexate added after 3 months, then hydroxychloroquine added at maximum tolerated dosage)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Parallel triple therapy (sulfasalazine, methotrexate, hydroxychloroquine)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Step-up therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Parallel triple therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Step-up therapy and Parallel triple therapy
Number of subjects: 96
Study: 16557155

Group type: EXPERIMENTAL
Intervention: 30:2 compression-to-ventilation ratio
Number of subjects: 20

Group type: COMPARATOR
Intervention: 15:2 compression-to-ventilation ratio
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30:2 compression-to-ventilation ratio with ITD
Number of subjects: 20
Study: 16279273

Group type: EXPERIMENTAL
Intervention: Nonparametric prediction methods using Kaplan-Meier estimator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parametric prediction model for failure-time outcomes
Number of subjects: 0
Study: 11504315

Group type: EXPERIMENTAL
Intervention: Surveillance after orchiectomy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 104
Study: 9217034

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (psychotherapy)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Chemotherapy and hormone therapy
Number of subjects: 86
Study: 7700061

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study: 3302112

Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg bd)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30076996

Group type: EXPERIMENTAL
Intervention: Experimental condition (learning to deceive)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control condition (no learning to deceive)
Number of subjects: 42
Study: 27149769

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) applied semi-annually
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Fluoride mouth rinse (FMR) once per week
Number of subjects: 1018
Study: 25618752

Group type: EXPERIMENTAL
Intervention: Combined add-on supplementation of omega-3 fatty acids, vitamin E, vitamin A, copper, and selenium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (soy oil)
Number of subjects: 100
Study: 22972879

Group type: EXPERIMENTAL
Intervention: Cystine (700 mg) and theanine (280 mg) administered for 10 days (4 days before to 5 days after surgery)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo administered for 10 days (4 days before to 5 days after surgery)
Number of subjects: 33
Study: 20601414

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (20 ml oral solution)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g intravenous)
Number of subjects: 234
Study: 18211575

Group type: EXPERIMENTAL
Intervention: Topical wound treatments
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Poor healing progress by early criteria at 4 weeks
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Diabetic foot ulcers and venous leg ulcers subgroups
Number of subjects: 547
Study: 16580189

Group type: EXPERIMENTAL
Intervention: Single office spirometry
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Minimal intervention strategy (control group)
Number of subjects: 1206
Study: 14563183

Group type: EXPERIMENTAL
Intervention: Methotrexate (i.v. 25 mg/week for 3 months, then oral 25 mg/week for 3 months)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Azathioprine (oral 2 mg/kg per day for 6 months)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 54

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 54
Study: 10908771

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 60 mg daily for 14 days
Number of subjects: 14
Study: 8720610

Group type: EXPERIMENTAL
Intervention: 250 mg acipimox
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1546351

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3986070

Group type: EXPERIMENTAL
Intervention: Zomepirac 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zomepirac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine
Number of subjects: 0
Study: 28920142

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study: 27118616

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided arthrocentesis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional arthrocentesis
Number of subjects: 20
Study: 25340399

Group type: EXPERIMENTAL
Intervention: Hungry participants in the Iowa Gambling Task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hungry participants in the delay discounting task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sated participants or participants with smaller appetite in the Iowa Gambling Task
Number of subjects: 0
Study: 22474203

Group type: EXPERIMENTAL
Intervention: Mammography plus ultrasound
Number of subjects: 2809

Group type: COMPARATOR
Intervention: Mammography alone
Number of subjects: 2809

Group type: EXPERIMENTAL
Intervention: Supplemental incidence-screening ultrasound
Number of subjects: 2809

Group type: EXPERIMENTAL
Intervention: MRI after mammography and ultrasound
Number of subjects: 2809

Group type: COMPARATOR
Intervention: Mammography and ultrasound
Number of subjects: 2809

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 2809

Group type: COMPARATOR
Intervention: Supplemental ultrasound
Number of subjects: 2809

Group type: COMPARATOR
Intervention: MRI after negative mammography and ultrasound results
Number of subjects: 2809
Study: 20823729

Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Treatment sessions targeting interoceptive and situational exposure exercises
Number of subjects: 379
Study: 18516070

Group type: EXPERIMENTAL
Intervention: Cranberry
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study: 15963091

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir plus efavirenz
Number of subjects: 69

Group type: COMPARATOR
Intervention: lopinavir/ritonavir plus nucleoside/nucleotide reverse transcriptase inhibitors
Number of subjects: 69
Study: 12373695

Group type: EXPERIMENTAL
Intervention: Gabapentin (daily dose titrated to 2400 mg or maximum tolerated dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 19
Study: 10676475

Group type: EXPERIMENTAL
Intervention: Serum zinc concentration analysis
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Hair zinc concentration analysis
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Overall zinc status assessment
Number of subjects: 1155
Study: 7586360

Group type: EXPERIMENTAL
Intervention: Low systemic heparin dose (ACT > 250 seconds; n = 17)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Full heparin dose (ACT > 480 seconds; n = 18)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (uncoated circuits with full heparin dose; n = 17)
Number of subjects: 52
Study: 2346795

Group type: EXPERIMENTAL
Intervention: FAST/LOW-YIELD
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: FAST/HIGH-YIELD
Number of subjects: 7

Group type: COMPARATOR
Intervention: FED/LOW-YIELD
Number of subjects: 7

Group type: COMPARATOR
Intervention: FED/HIGH-YIELD
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: FAST
Number of subjects: 7

Group type: COMPARATOR
Intervention: FED
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Laboratory session
Number of subjects: 7
Study: 508494

Group type: EXPERIMENTAL
Intervention: Trimetaphan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 24
Study: 31809970

Group type: EXPERIMENTAL
Intervention: 50 °C saline impregnated tampon and hot saline irrigation
Number of subjects: 130

Group type: COMPARATOR
Intervention: 22 °C saline impregnated tampon and saline irrigation
Number of subjects: 130
Study: 29985652

Group type: EXPERIMENTAL
Intervention: Ovoil™
Number of subjects: 101

Group type: COMPARATOR
Intervention: LiteOil®
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both oils
Number of subjects: 101
Study: 28676733

Group type: EXPERIMENTAL
Intervention: Paracervical Block (PB)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: IV Sedation (IVS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 84
Study: 26423784

Group type: EXPERIMENTAL
Intervention: Alteplase 10 mg (initially 20 mg was considered but reduced due to bleeding events)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Urokinase 100,000 UI every 24 h for a maximum of 6 days
Number of subjects: 99
Study: 23708690

Group type: EXPERIMENTAL
Intervention: Higher-protein formula (HP)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Lower-protein formula (LP)
Number of subjects: 351
Study: 20800241

Group type: EXPERIMENTAL
Intervention: Open group (cardiotomy suction and open venous reservoir)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nonsuction group (open venous reservoir without cardiotomy suction)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Closed group (without cardiotomy suction and open venous reservoir)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Open group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study: 19122549

Group type: EXPERIMENTAL
Intervention: AnaConDa
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (Conventional vaporizer)
Number of subjects: 24
Study: 17969886

Group type: EXPERIMENTAL
Intervention: Recipe for nourishing Gan-Shen
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (standard PD treatment)
Number of subjects: 121
Study: 11014981

Group type: EXPERIMENTAL
Intervention: Predialysis psychoeducation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard education (control)
Number of subjects: 47
Study: 8994317

Group type: EXPERIMENTAL
Intervention: TBE-vaccine (0.4 microgram)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: TBE-vaccine (0.75 microgram)
Number of subjects: 522

Group type: COMPARATOR
Intervention: TBE-vaccine (1.5 micrograms)
Number of subjects: 522
Study: 1479106

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/gm) twice daily for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (vehicle control)
Number of subjects: 0
Study: 6365838

Group type: EXPERIMENTAL
Intervention: Group Therapy (GT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 78
Study: 30117230

Group type: EXPERIMENTAL
Intervention: Numerical training
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 110
Study: 29905824

Group type: EXPERIMENTAL
Intervention: 8.8 g milk protein/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4.4 g milk protein/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4.4 g milk protein + 4.4 g rice protein/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-nitrogenous placebo
Number of subjects: 0
Study: 26889605

Group type: EXPERIMENTAL
Intervention: Methyl B12 (75 μg/kg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Methyl B12
Number of subjects: 57
Study: 24890528

Group type: EXPERIMENTAL
Intervention: Low-dose acetyl-salicylic acid (ASA)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Low-dose clonidine
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Placebo for acetyl-salicylic acid
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Placebo for clonidine
Number of subjects: 10000
Study: 23106885

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 60
Study: 20148772

Group type: EXPERIMENTAL
Intervention: Entropy-guided sevoflurane administration
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard practice sevoflurane administration
Number of subjects: 78
Study: 19402358

Group type: EXPERIMENTAL
Intervention: PMT-based treatment
Number of subjects: 700
Study: 16306545

Group type: EXPERIMENTAL
Intervention: Computer simulation model applied to baseline WESDR population with type 2 diabetes
Number of subjects: 0
Study: 12355675

Group type: EXPERIMENTAL
Intervention: Combination of psychotherapy and medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard pharmacologic interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard psychotherapies
Number of subjects: 0
Study: 10514397

Group type: EXPERIMENTAL
Intervention: Topical estrogen patch
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 36
Study: 7661588

Group type: EXPERIMENTAL
Intervention: Physical examination (PE) of the breast conducted by female health workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast self-examination (BSE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 0
Study: 1742002

Group type: EXPERIMENTAL
Intervention: Adjusted-dose heparin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: External pneumatic compression
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Functional electrical muscle stimulation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101